Alumis (ALMS) Competitors $3.31 -0.09 (-2.65%) Closing price 04:00 PM EasternExtended Trading$3.42 +0.11 (+3.44%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. SION, ANAB, NUVB, TRVI, DAWN, STOK, GHRS, SANA, URGN, and AUTLShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Sionna Therapeutics (SION), AnaptysBio (ANAB), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Day One Biopharmaceuticals (DAWN), Stoke Therapeutics (STOK), GH Research (GHRS), Sana Biotechnology (SANA), Urogen Pharma (URGN), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors Sionna Therapeutics AnaptysBio Nuvation Bio Trevi Therapeutics Day One Biopharmaceuticals Stoke Therapeutics GH Research Sana Biotechnology Urogen Pharma Autolus Therapeutics Sionna Therapeutics (NASDAQ:SION) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Does the media favor SION or ALMS? In the previous week, Sionna Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 5 mentions for Sionna Therapeutics and 0 mentions for Alumis. Sionna Therapeutics' average media sentiment score of 1.15 beat Alumis' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sionna Therapeutics Positive Alumis Neutral Do analysts recommend SION or ALMS? Sionna Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 83.68%. Alumis has a consensus price target of $22.86, indicating a potential upside of 590.55%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Is SION or ALMS more profitable? Sionna Therapeutics' return on equity of 0.00% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Alumis N/A -406.27%-107.29% Which has better earnings & valuation, SION or ALMS? Sionna Therapeutics has higher earnings, but lower revenue than Alumis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AAlumis$17.39M10.36-$294.23MN/AN/A SummarySionna Therapeutics and Alumis tied by winning 5 of the 10 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$180.08M$2.86B$5.45B$8.93BDividend YieldN/A2.44%5.22%4.01%P/E RatioN/A20.4427.2420.06Price / Sales10.36283.79426.37117.54Price / CashN/A41.7026.2128.59Price / Book0.607.397.925.56Net Income-$294.23M-$55.04M$3.17B$248.56M7 Day Performance10.33%3.43%4.40%7.56%1 Month Performance-7.80%0.16%2.64%8.54%1 Year PerformanceN/A4.49%35.04%21.81% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.8842 of 5 stars$3.31-2.6%$22.86+590.5%N/A$180.08M$17.39M0.00N/AGap DownSIONSionna TherapeuticsN/A$15.05+1.5%$38.50+155.8%N/A$664.01MN/A0.0035Gap UpANABAnaptysBio2.268 of 5 stars$22.58-3.4%$42.38+87.7%-2.8%$663.25M$91.28M-4.65100NUVBNuvation Bio3.4308 of 5 stars$1.95-1.3%$7.17+268.5%-31.2%$661.81M$7.87M-0.8360TRVITrevi Therapeutics3.2631 of 5 stars$5.61-0.9%$20.29+261.6%+128.5%$659.76MN/A-12.5020DAWNDay One Biopharmaceuticals1.6952 of 5 stars$6.41-1.2%$30.57+377.3%-50.4%$649.21M$131.16M-9.0260Upcoming EarningsSTOKStoke Therapeutics3.9893 of 5 stars$11.71-1.1%$23.20+98.1%-12.5%$642.92M$36.56M14.91100GHRSGH Research1.5627 of 5 stars$12.34-0.5%$32.00+159.3%+26.9%$641.53MN/A-15.6110Analyst UpgradeSANASana Biotechnology2.5529 of 5 stars$2.83-1.6%$8.60+204.4%-37.2%$636.98MN/A-3.21380URGNUrogen Pharma4.5451 of 5 stars$13.38+2.1%$32.86+145.6%-15.1%$621.10M$90.40M-4.24200Analyst ForecastAUTLAutolus Therapeutics2.1099 of 5 stars$2.30-0.6%$9.32+306.1%-31.3%$611.86M$10.12M-2.61330 Related Companies and Tools Related Companies SION Alternatives ANAB Alternatives NUVB Alternatives TRVI Alternatives DAWN Alternatives STOK Alternatives GHRS Alternatives SANA Alternatives URGN Alternatives AUTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALMS Stock Alerts